Who deserves the cut?

This editorial is wary of the rise of efforts to insert immune checkpoint inhibitors (ICI) in lieu of radiation for the neoadjuvant treatment of esophageal and non-small cell lung cancers that, while intriguing, certainly leave room for improvement; in fact, given the plethora of data for both safety and synergy with concurrent delivery of thoracic radiation and ICI, perhaps…dun dun dun…surgery is the one that needs to go. | Chang, JAMA Oncol 2022